2 results
Approved WMOCompleted
To assess the effect of switching CML patients, who have been treated with imatinib *2 years and who have stable detectable molecular residual disease above 0.01% (IS), to the combination of Nilotinib and PegIFN, in terms of the proportion of…
Approved WMORecruiting
This study has three specific objectives:1) to explore how the participants* intercorporal bone grafts HU develop over time in the first two years after fusion surgery.2) to explore the interobserver reliability of the HU measurements.3) to explore…